**Ongoing prospective trials**

**Location:** Room Vienna, North Hall (Level 1)

**Chairs:**
- J. Bellmunt, Barcelona (ES)
- M. Retz, Munich (DE)
- S. Shariat, Vienna (AT)

**Aims and objectives of this session**
To show what is currently going on in oncologic urology and other fields in urology regarding multicentre prospective randomized studies.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

14:38 - 14:48

**Overview on systematic reviews/meta analysis**

S. Shariat, Vienna (AT)

---

206

**A phase 3 randomized, double-blind, placebo-controlled trial of ODM-201 vs. placebo in combination with standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer (ARASENS)**

By: Smith M.\(^1\), Saad F.\(^2\), Hussain M.\(^3\), Sternberg C.\(^4\), Fizazi K.\(^5\), Crawford D.\(^6\), Yamada K.\(^7\), Kappeler C.\(^8\), Kuss I.\(^9\), Tombal B.\(^9\)

**Institutes:** Massachusetts General Hospital Cancer Center and Harvard Medical School, Dept. of Urologic Oncology, Boston, United States of America, \(^1\); University of Montreal, University of Montreal Hospital Center/CRCHUM, Montreal, Canada, \(^2\); Northwestern University Feinberg School of Medicine, Dept. of Hematology/Oncology, Chicago, United States of America, \(^3\); San Camillo and Forlanini Hospitals, Dept. of Medical Oncology, Rome, Italy, \(^4\); Gustave Roussy, University of Paris Sud, Cancer Medicine, Villejuif, France, \(^5\); University of Colorado, Dept. of Urologic Oncology, Aurora, United States of America, \(^6\); Bayer Pharmaceuticals, Dept. of Oncology, Whippany, United States of America, \(^7\); Bayer Pharma AG, Dept. of Oncology, Berlin, Germany, \(^8\); Cancer Centre, Catholic University of Louvain (UCL), Dept. of Urology, Brussels, Belgium

---

207

**Prostate cancer intra-tumoral heterogeneity: Correlation between clinical parameters, mpMRI and biomarkers**

By: Carmona Echeverria L.M.\(^1\), Johnston E.\(^2\), Shanmugabavan Y.\(^3\), Rowan A.\(^4\), Goh G.\(^5\), Scott R.\(^5\), Hung M.\(^6\), Geling M.\(^6\), Arya M.\(^7\), Emberton M.\(^7\), Freeman A.\(^7\), Punwani S.\(^7\), Barrat D.\(^8\), Yipeng H.\(^8\), Attard G.\(^8\), Whitaker H.\(^1\), Linch M.\(^5\), De Bono J.\(^9\), Swanston C.\(^4\), Ahmed H.\(^8\)

**Institutes:** University College London, Dept. of Surgery and Interventional Science - Centre For Molecular Intervention, London, United Kingdom, \(^1\); University College London, UCL Centre For Medical Imaging, London, United Kingdom, \(^2\); University College London, Dept. of Surgery and Interventional Science, London, United Kingdom, \(^3\); Cancer Research UK, Translational Cancer Therapeutics Laboratory, London, United Kingdom, \(^4\); University College London Cancer Institute, London, United Kingdom, \(^5\); Institute of Cancer Research, Centre For Evolution and Cancer, London, United Kingdom, \(^6\); University College London, Dept. of Research Pathology, London, United Kingdom, \(^7\); University College London, UCL Centre For Medical Image Computing, London, United Kingdom, \(^8\); Institute of Cancer Research, Dept. of Clinical Studies, London, United Kingdom

---

208

**KEYNOTE-365: Phase 1b/2 trial of pembrolizumab combination therapy for metastatic castration-resistant prostate cancer (mCRPC)**

By: Yu E.Y.\(^2\), Wu H.\(^1\), Schloss C.\(^1\)

**Institutes:** Merck & Co., Inc., Dept. of Clinical Oncology, Kenilworth, United States of America, \(^2\); Seattle Cancer Care Alliance, Dept. of Medicine, Seattle, United States of America
**Poster Session 16**

**209**

Multi-institutional validation and assessment of training modalities in robotic surgery (the MARS project)

*By: Raison N.\(^1\), Ahmed K.\(^1\), Aydin A.\(^2\), Van Der Poel H.\(^3\), Mottrie A.\(^4\), Dasgupta P.\(^2\)*

**Institutes:** King’s College London, London, United Kingdom; King’s College London, MRC Centre For Transplantation, London, United Kingdom; Netherlands Cancer Institute, Amsterdam, The Netherlands; OLV Clinic, Aalst, Belgium

**210**

The effects of the human fetal estrogen estetrol (E4) in healthy men to estimate its potential use for the treatment of prostate cancer

*By: Dutman E., Zimmerman Y., Coelingh-Bennink H.*

**Institutes:** Pantarhei Oncology BV, Zeist, The Netherlands

**211**

PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miUBC)

*By: Necchi A.\(^1\), Mariani L.\(^2\), Anichini A.\(^3\), Giannatempo P.\(^4\), Raggi D.\(^5\), Togliardi E.\(^6\), Calareso G.\(^7\), Nicolai N.\(^8\), Crippa F.\(^9\), Torelli T.\(^5\), Stagni S.\(^8\), Piva L.\(^9\), Salvioni R.\(^10\)*

**Institutes:** Fondazione IRCCS - Istituto Nazionale Dei Tumori, Milan, Italy; Fondazione IRCCS - Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy; Fondazione IRCCS - Istituto Nazionale Dei Tumori, Human Tumors Immunobiology Unit, Milan, Italy; Fondazione IRCCS - Istituto Nazionale Dei Tumori, Department of Pharmacy Unit, Milan, Italy; Fondazione IRCCS - Istituto Nazionale Dei Tumori, Department of Radiology, Milan, Italy; Fondazione IRCCS - Istituto Nazionale Dei Tumori, Department of Urology, Milan, Italy; Fondazione IRCCS - Istituto Nazionale Dei Tumori, Nuclear Medicine and PET Unit, Milan, Italy

**212**

IMvigor010, a phase III study of adjuvant atezolizumab vs observation in patients (pts) with muscle-invasive urothelial carcinoma (UC)

*By: Gschwend J.\(^1\), Bellmunt J.\(^2\), Castellano D.\(^3\), Daneshmand S.\(^4\), Hussain M.\(^5\), Nishiyama H.\(^6\), Powles T.\(^7\), Degaonkar V.\(^8\), Nguyen Duc A.\(^9\), Culine S.\(^10\)*

**Institutes:** Technical University of Munich, Dept. of Urology, Munich, Germany; Bladder Cancer Center, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, United States of America; Hospital Universitario 12 De Octubre, Dept. of Oncology, Madrid, Spain; University of Southern California, Dept. of Oncology, Los Angeles, United States of America; Northwestern University, Dept. of Oncology, Chicago, United States of America; University of Tsukuba, Dept. of Oncology, Ibaraki, Japan; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Genentech, Inc., Dept. of Oncology, South San Francisco, United States of America; Roche, Dept. of Oncology, Basel, Switzerland; Hôpital Saint-Louis, Dept. of Oncology, Paris, France

**213**

Phase 3 randomized trial of intravenous mannitol versus placebo prior to renal ischemia during partial nephrectomy: Impact on renal functional outcomes

*By: Spaliviero M., Power N., Murray K., Sjoberg D., Benfante N., Bernstein M., Wren J., Russo P., Coleman J.*

**Institutes:** Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America

**214**

A phase 2 trial of lenvatinib in combination with everolimus in patients with advanced or metastatic non-clear cell renal cell carcinoma

*By: Hutson T.\(^1\), Xing D.\(^2\), Dutcus C.\(^3\), Baig M.\(^4\), Fishman M.\(^4\)*

**Institutes:** Texas Oncology, Dallas, United States of America; Eisai, Woodcliff Lake, United States of America; Eisai, OBG, Woodcliff Lake, United States of America; H. Lee Moffitt, Cancer and Research Center, Tampa, United States of America

**215**

A national, prospective, non-interventional study (NIS) of nivolumab (BMS-936558) in patients with advanced renal cell carcinoma after prior therapy

*By: Grimm M-O., Grünwald V., Bedke J.*
216

**APACHE: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab (D, MEDI4736), alone or in combination with Tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)**


**Institutes:** Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, *Fondazione IRCCS - Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, *Fondazione IRCCS - Istituto Nazionale Dei Tumori, Human Tumors Immunobiology Unit, Milan, Italy, *Fondazione IRCCS - Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, *Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, *Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, *Fondazione IRCCS - Istituto Nazionale Dei Tumori, Nuclear Medicine and PET Unit, Milan, Italy

217

**An effective and acceptable cleaning method for re-use of catheters for intermittent catheterisation (IC)**


**Institutes:** University of Southampton, Dept. of Health Sciences, Southampton, United Kingdom, *Bristol Urological Institute, Dept. of Learning and Research, Bristol, United Kingdom, *University of Alberta, Faculty of Nursing, Alberta, Canada, *University College London, Continence & Skin Technology Group, London, United Kingdom

**Summary**

J. Bellmunt